EyePoint Pharmaceuticals

Press Release

<< Back
Jul 21, 2015

pSivida CEO to Speak at Controlled Release Society Annual Meeting Workshop in Edinburgh, Scotland, This Weekend

WATERTOWN, Mass.--(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced Dr. Paul Ashton, president and CEO of pSivida Corp., will speak at a special workshop focusing on ocular drug delivery just prior to the start of the Controlled Release Society (CRS) 2015 Annual Meeting being held July 26-29 in Edinburgh, Scotland. Dr. Ashton will address "The Complete Story - Going through Regulatory Approval" during the "Ocular Drug Delivery - Challenges of Matching New Technologies with Drug Pharmacokinetics" workshop to be held on Saturday, July 25.

pSivida's patented Durasert™ technology, which can deliver drug for a predetermined period ranging from months to years, is the basis of three of the only four sustained release products approved by the FDA to treat back of the eye diseases. The most recent is ILUVIEN® for diabetic macular edema. Medidur™ for posterior uveitis is in Phase III clinical trials. These products, which use the same injectable micro-insert, provide sustained delivery of a corticosteroid to the back of the eye for three years from a single injection.

According to the organizers, "The global ophthalmic pharmaceutical market is expected to be worth $22 billion by 2018. Yet only four intraocular slow release systems are approved today, due in part to the challenges of matching new technologies with drug pharmacokinetics." This workshop is one of the first to be held by the society that will focus specifically on Ocular Drug Delivery. pSivida is also a sponsor of the workshop.

The Controlled Release Society (CRS) is the premier international, multidisciplinary society dedicated to delivery science and technology. CRS serves members from industry, academia and government in more than 50 countries worldwide who have an interest in drug delivery and other delivery applications in consumer and diversified products and animal health. CRS provides innovative research, targeted networking and career advancement to its membership.

About pSivida Corp.

pSivida Corp. (www.psivida.com), headquartered in Watertown, MA, is a leader in the development of sustained release, drug delivery products for treating eye diseases. pSivida has developed three of only four FDA-approved treatments for back-of-the-eye diseases. The most recent, ILUVIEN®, a micro-insert for diabetic macular edema, is licensed to Alimera Sciences and sold in the U.S. and three EU countries. Retisert®, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSivida's lead product candidate, Medidur™, a micro-insert for posterior uveitis, is currently in pivotal phase III clinical trials with an NDA anticipated in the first half of 2017. pSivida's preclinical development program is focused on using its core platform technologies, Durasert™ and/or Tethadur™, to deliver drugs and biologics to treat wet and dry age-related macular degeneration (AMD), glaucoma, osteoarthritis and other diseases.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statement Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements include uncertainties with respect to: actual final IOP safety results for Medidur Phase III trials; ability to achieve profitable operations and access to capital; fluctuations in operating results; further impairment of intangible assets; decline in Retisert royalties; successful commercialization of, and receipt of revenues from, ILUVIEN for DME; effect of pricing and reimbursement decisions on sales of ILUVIEN for DME; consequences of fluocinolone acetonide side effects; number and cost of clinical trials and data necessary to support an NDA for, approval by Indian regulators of the trial design for, timing of filing the NDA for, and regulatory approval and successful commercialization of, Medidur; delays in completion of clinical trials; increases in cost of clinical trials; changes in, or misunderstandings with respect to, FDA guidance on required clinical trials; development of the Latanoprost Product and any exercise by Pfizer of its option; ability of Tethadur to successfully deliver large biologic molecules and to develop products using it; ability to successfully develop product candidates, complete clinical trials and receive regulatory approvals; ability to market and sell products; success of current and future license agreements; termination of license agreements; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; legislative or regulatory changes; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the SEC. You should read and interpret any forward-looking statements together with these risks. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

Follow pSivida on social media:

Twitter: https://twitter.com/pSividaCorp
Facebook: https://www.facebook.com/pages/PSivida-Corp/544893792199562
LinkedIn: http://www.linkedin.com/company/psivida
Google+: https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts
The President's Blog: http://www.thechairmansblog.com/paul-ashton

For more information on pSivida, visit www.psivida.com.

Martin E. Janis & Company, Inc.
Beverly Jedynak
T: 312-943-1123
M: 773-350-5793

Source: pSivida Corp.

News Provided by Acquire Media

EyePoint Pharmaceuticals